Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02519621
Recruitment Status : Completed
First Posted : August 11, 2015
Results First Posted : August 14, 2020
Last Update Posted : August 14, 2020
Sponsor:
Information provided by (Responsible Party):
Larry Lavery, University of Texas Southwestern Medical Center

Brief Summary:
This study is designed to assess the efficacy and economics of two NPWT (negative pressure wound therapy) branded devices of wound healing outcomes. It is also designed to assess the effectiveness of negative pressure and negative pressure with continuous irrigation on multiple parameters of wound healing. It is a single-center, open-label, active controlled, parallel-group trial that aims to determine the efficacy of Quantum with simultaneous irrigation in the treatment of diabetic foot ulcers. Specifically, eligible participants will be randomized to receive either PRO negative press therapy with simultaneous irrigation; or PRO negative pressure therapy without irrigation; or KCI Ulta negative pressure therapy. Outcomes will include rates of wound healing, time to closure, number of surgeries, length of stay, and days to heal.

Condition or disease Intervention/treatment Phase
Partial-thickness Burn Ulcer Device: NPWT PRO without irrigation Device: NPWT PRO with irrigation Device: KCI Ulta Not Applicable

Detailed Description:

Subjects will be taken to the operating room for the initial debridement procedure of the wound. At the end of the procedure, subjects who continue to meet all inclusion and no exclusion criteria will be randomized in a 1:1:1 ratio to be treated with either PRO, PRO with simultaneous irrigation (PROI), or KCI Ulta NPWT. Prior to study initiation sealed prenumbered randomization envelopes will be provided to the research staff and used to obtain randomization assignment. Opening of the randomization envelope will occur intraoperatively at the conclusion of the initial surgical debridement of the wound and conformation of all eligibility requirements. Study staff will use the randomization number labels contained in the envelop. The number will become the subject ID. The assignment will be subjects randomized to PRO, PRO with simultaneous irrigation, or KCI Ulta NPWT.

The research staff will note treatment assignments on the intra operative randomization CRF and instruct the investigator. Treatment therapy wound dressings will be applied in the operating room or in the patient's room immediately after surgery per the investigators discretion, according to the manufacturer's recommendations. In order to ensure consistent study treatment, subjects will receive assigned treatment therapies within their study arm after the initial and any subsequent surgical debridements until the wound is deemed ready for closure or coverage by the Investigator. Subjects randomized to the PRO with simultaneous irrigation Treatment arm are the only subjects that will receive irrigation therapy at any time during the study treatment period. If irrigation therapy is discontinued, subjects in the Treatment arm will transition to PRO NPWT without irrigation. Subjects randomized to the PRO Control arm will receive NPWT only from the PRO therapy unit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study to Compare the Efficacy of NPWT PRO Versus KCI Ulta® NPWT and to Compare NPWT PRO Versus NPWT PRO With Simultaneous Irrigation on Wound Healing
Actual Study Start Date : April 2016
Actual Primary Completion Date : January 2019
Actual Study Completion Date : June 24, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: NPWT PRO without irrigation
Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage
Device: NPWT PRO without irrigation
NPWT PRO without irrigation.
Other Name: Cardinal Quantum NPWT PRO

Active Comparator: NPWT PRO with Irrigation
Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant).
Device: NPWT PRO with irrigation
NPWT PRO with irrigation (saline)
Other Name: Cardinal Quantum NPWT PRO

Active Comparator: KCI Ulta NPWT
KCI Ulta NPWT without irrigation.
Device: KCI Ulta
KCI Ulta NPWT without irrigation




Primary Outcome Measures :
  1. Number of Participants Who Achieved Complete Wound Healing [ Time Frame: 12 weeks ]
    Complete healing of wounds as defined by epithelialization with no drainage in three treatment arms: NPWT PRO versus KCI Ulta® NPWT and to Compare NPWT PRO versus NPWT PRO with Simultaneous Irrigation


Secondary Outcome Measures :
  1. Number of Surgeries [ Time Frame: 12 weeks ]
    Number of surgeries required to debride infection before wound was ready for closure or coverage.

  2. Length of Stay [ Time Frame: 12 weeks ]
    Number of days the patient stayed in the hospital

  3. Days to Heal [ Time Frame: 12 weeks ]
    The number of days to heal the wound after last surgery was performed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Presents with an existing chronic or traumatic wound, sub-acute or dehisced wound, partial-thickness burn, ulcer (such as a diabetic or pressure ulcer), flap or graft as diagnosed by a qualified and certified medical practitioner (M.D., D.O., or D.P.M)
  • Wound presents with full thickness loss of epidermis and dermis
  • The presentation of a wound that in the opinion of the investigators will require surgical debridement, and the wound is expected to be a good candidate for NPWT and eventual wound closure.
  • ABI≥0.5 or toe pressures >30 PVR/mmHg
  • Subject is willing and able to abstain from partaking in any other form of treatment for his or her wound throughout the duration of his or her course of participation in the clinical study, other than the study procedures described herein.
  • 18 years of age or older

Exclusion Criteria:

  • Does not present with an existing chronic or traumatic wound, sub-acute or dehisced wound, partial-thickness burn, ulcer (such as a diabetic or pressure ulcer), flap or graft, or a definitive diagnosis cannot be made, as diagnosed by a qualified and certified medical practitioner (M.D., D.O., or D.P.M)
  • Wound does not present with full thickness loss of epidermis and dermis
  • ABI<0.5 or toe pressures <30 PVR/mmHg
  • Subject is not willing or is not able or it is not medically prudent for the subject to abstain from partaking in any other form of treatment for his or her wound throughout the duration of his or her course of participation in the clinical study, other than the study procedures described.
  • Subject is unwilling or unable to use the NPWT device at home
  • Active Charcot arthropathy
  • Collagen vascular disease
  • Scleroderma
  • Non-enteric and unexplored fistula
  • Necrotic tissue with eschar present after debridement
  • General skin disorder in the area of the wound such as psoriasis or penicilitis
  • Malnutrition (defined as BMI <19)
  • Hypercoagulable state based on documentation in their medical record
  • Acute deep vein thrombosis
  • Current active malignancy in the wound
  • Current melanoma or history of melanoma at the wound
  • Current active or history of invasive squamous cell carcinoma at the wound
  • Sepsis (defined as positive blood culture with leukocytosis) and temperature >101.5 at the time of screening
  • Significant Hematologic disorders EXCLUDING anemia
  • HIV
  • Fever at screening > 101.5
  • Deep X-ray therapy
  • Untreated bone or soft tissue infection (osteomyelitis)
  • Any concomitant illness(es) or medical condition(s) that in the opinion of the investigator would render the subject not suited for study participation
  • Subject is taking a regimen of any medication(s) in a significant enough dosage that may affect chronic wound healing, including corticosteroid, chemotherapeutic and non-steroidal anti-inflammatory (NSAID) medications
  • Less than 18 years of age
  • Developmental disability/significant psychological disorder that could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures, including schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years.
  • Females currently pregnant or planning pregnancy during the course of intended participation in the study
  • Active alcohol or substance abuse in the opinion of the investigator that could impair the subjects ability to provide informed consent, participate in the study protocol or record study measures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02519621


Locations
Layout table for location information
United States, Texas
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
UT Southwestern
Dallas, Texas, United States, 75390
Sponsors and Collaborators
Larry Lavery
Investigators
Layout table for investigator information
Principal Investigator: Lawrence A Lavery, DPM UT Southwestern Medical Center
  Study Documents (Full-Text)

Documents provided by Larry Lavery, University of Texas Southwestern Medical Center:
Layout table for additonal information
Responsible Party: Larry Lavery, Professor and Director of Research, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT02519621    
Other Study ID Numbers: STU 032015-099
First Posted: August 11, 2015    Key Record Dates
Results First Posted: August 14, 2020
Last Update Posted: August 14, 2020
Last Verified: August 2020
Keywords provided by Larry Lavery, University of Texas Southwestern Medical Center:
diabetic ulcer
pressure ulcer
chronic or traumatic wound
sub-acute or dehisced wound
Additional relevant MeSH terms:
Layout table for MeSH terms
Ulcer
Pathologic Processes